Click here to view online. Add this email to your safelist.

AstraZeneca logo

Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

15 December 2025

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, as determined by a Food and Drug Administration (FDA)-approved test.

Read more  Read more

RSS Feed  RSS Feed Twitter/X  Follow us on X LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2025

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.